Britain’s cost-effectiveness watchdog to cancer sufferers: ‘No life-extending drugs for you’

Just as is expected under Obamacare (Obama even admitted to rationing), Britain’s cost-effectiveness watchdog - The National Institute for Health Clinical Excellence (NICE), has blocked the use of a life-extending breast cancer drug on the NHS, despite a fresh review of the medicine saying that it still did not feel GlaxoSmithKline’s drug Tyverb was a cost-effective use of resources. NICE’s action will result in 2,000 British women a year being denied access to the drug.

This story is not unlike what we’ve seen in Oregon through it’s socialized medicine plan where a woman was denied cancer drug but offered assisted suicide because it was cheaper for her to die than to pay for a drug to save her life.

Bookmarks

Related News

• The protest at the AHIP insurance company conference in DC was astroturfed
• Obama’s doctor cousin blasts Obamacare
• Article: Dropping the Bomb on Health Care
• Choosy Moms Don’t Choose Socialized Medicine
• Live Or Let Die - The Truth About The "Death Panel" section
• Wherein We Find That Britain’s Government "Option" Is a Pain in the Back
• Socialized Medicine In Action
• (Video) Obama tells woman instead of a pacemaker we might give old ladies a pill
• Under UK socialized medicine, Disabled children wait up to two years for wheelchairs
• Streaming and Interactive at 5:00: Health Reform Director Nancy-Ann DeParle